Identification association of drug-disease by using functional gene module for breast cancer by Lida Zhu & Fuxi Zhu
RESEARCH ARTICLE Open Access
Identification association of drug-disease by using
functional gene module for breast cancer
Lida Zhu1*, Fuxi Zhu2*
From The 4th Translational Bioinformatics Conference and the 8th International Conference on Systems
Biology (TBC/ISB 2014)
Qingdao, China. 24-27 October 2014
Abstract
In oncology drug development, it is important to develop low risk drugs efficiently. Meanwhile, computational
methods have been paid more and more attention in drug discovery. However, few studies attempt to discover
the mutual gene modules shared by the drug and disease association. Here we introduce a novel method to
identify repositioned drug for breast cancer by integrating the breast cancer survival data with the drug sensitivity
information. Among the 140 drug candidates, we are able to filter 4 FDA approved drugs and identify 2 breast
cancer drugs among 4 known breast cancer therapeutic drug in total.
Introduction
The goal of drug repositioning is to discover new asso-
ciation between indications of diseases and known drugs
based on known associations [1]. Drug repositioning
provides a possible way to speed up the drug develop-
ment and avoids the development cost and time con-
suming in the drug discovery. For example, the Pfizer’s
Viagra and Celgene’s thalidomide are both successful
examples that are used to treat new application rather
than the designed indication during the development
stage [2-4]. However, the mechanism of how drugs and
diseases are associated in the gene regulatory network is
still mysterious. Therefore, the need of developing a sys-
tematic approach to discover disease-drug association
from the complicate heterogeneity data is urgent.
Roughly speaking, both human diseases and drug mode
of action have a module basis on gene expression level.
The rapidly developed microarray technique generates a
huge amount of large-scale gene expression profiles. The
gene expression data are both applied in cancer diagnosis
and therapy. To identify the phenotype relevant gene
modules could help us understand the mechanism of
diseases and provides opportunities to develop new
therapies. It is important to investigate the drug induced
gene modules, and the differential expressed functional
gene modules that influenced by diseases, especially the
shared associated gene modules of drugs and disease
phenotypes. Few analyses addressed the above questions
in a systematic view. Gottlieb et al. presented a prediction
method that based on the observation that similar drugs
are indicated for similar diseases, and then discovers new
associations by imposing the known “drug-disease”
connections. Cheng et al. proposed a network-based
inference method to predict new target for known drugs
by using drug target bipartite network topology similarity
[5,6]. With the emerging development of the microarray
technology, some researches focused on using the gene
expression data as the connection between drug and
disease for drug repositioning. For example, “the Connec-
tivity Map” (CMAP) project developed a reference collec-
tion of gene expression profiles by treating cultured
human cells with small molecules, and searched for the
compounds that have the most negative correlation with
the disease’s gene expression profiles as the potential can-
didate [7,8]. However, due to the limitation of the level of
gene expression profiles among the above works, the
molecular mechanism of diseases still remains unknown.
Recently, some studies suppose that cellular components
belonging to the same topological, functional or disease
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module have a high likelihood of being involved in similar
diseases [9,10]. Thus one can start with identifying the
gene modules that associate with the topological, func-
tional and disease. The gene modules here is defined by
the group of genes that annotated by biological process or
cellular component or molecular function terms in Gene
Ontology [11,12]. There are several studies proposed to
characterize different disease modules. The investigation
on drug action of the gene modules had shown effective
results. Li et al., by using Gene Ontology, defined the
Gene Ontology Module (GOM) and investigated the dis-
ease’s biological mechanism, and then successfully identi-
fied several repositioned drugs by using the similarity of
GOM [13]. Xia et al. used Gene Ontology Term to define
the miRNA target gene’s function in various disease, and
used it to predict several potential treatments [14]. Since
the prognosis studies were also sampled by high through-
put gene expression profiles, in this work we present how
to make use of this kind of clinical prognosis data and
initiate the mutual gene modules to investigate drug repo-
sitioning for the treatment of breast cancer. The definition
of the mutual gene module of disease is based on the
Gene Ontology Cellular Component Terms and Gene
Ontology Biological Process Term. We selected the gene
modules that have significant association with tumor pro-
gression by applying t-test in multiple prognostic clinical
trials. In the meanwhile, we define a sensitivity module of
drugs to interrogate the mechanism of drug actions. The
sensitivity module for each anti-cancer drug (in total 140)
is generated by integrating the sensitivity data (e.g. GI50)
from the Developmental Therapeutic Program (DTP
http://dtp.nci.nih.gov/) database. Combining with the
prognosis modules and drug sensitivity modules, a reposi-
tioning framework for breast cancer is built. As a result,
we have identified 12 compounds related to breast cancer.
Interestingly, Not only could they help in treatment, but
some of them could also have caused the disease.
Material and method
Here we proposed a systematic framework to identify
the potential candidate drug for breast cancer and the
associated mechanism module. The framework consists
of three parts: (1) Identifying the prognosis module. The
prognosis module is selected based on the statistical dif-
ferences between the good outcome and bad outcome
of the patients in three breast cancer clinical trials. (2)
Generation of the sensitivity module network of drugs.
The sensitivity module network of drugs is used to
interrogate the mechanism of drug action. (3) Integra-
tion of the two results to search for the potential candi-
date drug. In the last step, we integrated the disease
gene modules with the anti-cancer drug sensitivity mod-
ule to filter the most significant potential anticancer
treatment for breast cancer as shown in Figure 1.
Data description
The tumor progression associated information is collected
from three breast cancer datasets (GSE2034 [15],
GSE7390 [16] and GSE11121 [17]). These data are used to
select the differential expressed gene modules associated
to the prognosis outcome among all the patient samples.
The drug information was downloaded from DTP
database, which contains 172 anti-cancer compounds in
total [18,19]. The format of the analyzed data is shown
in Table 1. After matched with the GI50 value in 60
NCI cell lines [20], the sensitivity geneset was generated
for the remaining140 drugs.
Gene module enrichment analysis
A gene module was defined by a group of genes that
sharing a similar function or regulation mechanism.
Here we used the Gene Ontology as an example. The
Gene Ontology was annotated into three categories:
Biological Process (GOBP), Cellular Component
(GOCC) and Molecular Function (GOMF). The anno-
tated Gene Ontology Term was considered as a gene
module.
To determine the universal prognosis gene modules
that represent breast cancer pathologic information,
gene set enrichment analysis is performed on three dif-
ferent breast cancer survival datasets, with the purpose
of selecting the gene sets that express significantly
enriched in the survived patients. First, the gene sets
were adopted from GOCC and GOBP. For each breast
cancer expression dataset, we have n samples. Then the
Kolmogorov-Smirnov (KS) statistic is employed to test
whether the expression of the gene set is enriched
among the whole gene expression (N) in each sample.











Figure 1 The workflow of the method that integrated the
prognostic gene modules with the drug sensitivity modules.
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where t is the number of the genes in the gene set, j is
the jth gene according to the ranked expression in the
gene set, N is the total number (13698) in the gene
expression profile, V(j) is the ranked position of the jth
gene, and KS score represents the enrichment score of
each gene set in each sample. The result of this analysis
is a matrix generated by the enrichment score of each
gene module in each sample.
Identification of prognosis gene modules
For each disease dataset, we used the t-test (as shown in
formula (4)) to find whether the gene set has significant
differential enrichment scores between the good out-
come and bad outcome. And then we selected those










where x stands for the average enrichment score of
the survived patient, y stands that of the patient with
bad outcome, n is the number of the survived patients,
and m is the number of the rest of the patients.
Identification of drug sensitivity genes
Here we measure the drug sensitivity signature based on
National Cancer Institute (NCI60) in vitro drug screen
project [20]. The subset of compounds in this study was
defined in the “Standard Agent Database” from DTP
website [18,19]. The drug sensitivity genes were identified
by the close correlation of the baseline expression of gene
among 60 cell lines with the chemical activity of a treated
drug on the same 60 cell lines. On one hand, since the
NCI60 cell lines screen panel has proved to be an effec-
tive way to identify drug sensitivity specific biomarkers as
the panel has already been comprehensively character-
ized via gene expression profiling. Therefore, the gene
expression profile of NCI60 is used to measure the base-
line of gene expression and represented by a matrix of
gene expression profile in 60 cell lines. On the other
hand, the biological response pattern is measured by GI50
value, which is the compound’s concentration that causes
50% cell growth inhibition and was obtained from DTP.
Since the GI50 value is represented the drug’s chemo-
activity, the gene-drug correlation is established based on
the correlation of gene expression and drug activity
across 60 cell lines. The sensitivity module is consisted of
only the significant gene that has P-value<0.05 as the
compound sensitivity associated gene.
Generalization of the drug-disease connection
The drug-disease link is established based on the P-value of
the hyper-geometric test (5) to determine whether the gene
module (from the selected prognosis gene modules) has a







where M is the total number of genes in the whole
profiles, N is the number of the prognosis gene mod-
ules, m is the number of the sensitivity module of the
drug, and n is the number of the overlap between the
prognosis module and the sensitivity module.
The performance analysis of the identification of drugs
As shown in the final step of Figure 1, a ranked list of
the modules and the selected prognosis modules was
Table 1. The format of the analyzed drug
NSC LCONC PANEL CELL NLOGGI50 Compound CAS
740 -5 Renal 786-0 7.644 methotrexate 1959-5-2
740 -5 Renal A498 5 methotrexate 1959-5-2
740 -8.6 Non-Small Cell Lung A549-ATCC 8.602 methotrexate 1959-5-2
740 -3.6 Renal ACHN 7.308 methotrexate 1959-5-2
740 -3.6 Breast BT-549 4.651 methotrexate 1959-5-2
740 -3.6 Renal CAKI-1 7.124 methotrexate 1959-5-2
740 -3.6 Leukemia CCRF-CEM 7.508 methotrexate 1959-5-2
740 -8.6 Colon COLO 205 8.602 methotrexate 1959-5-2
740 -5 Prostate DU-145 7.238 methotrexate 1959-5-2
740 -8.6 Non-Small Cell Lung EKVX 8.602 methotrexate 1959-5-2
740 -5 Colon HCC-2998 7.025 methotrexate 1959-5-2
740 -8.6 Colon HCT-116 8.89 methotrexate 1959-5-2
Zhu and Zhu BMC Medical Genomics 2015, 8(Suppl 2):S3
http://www.biomedcentral.com/1755-8794/8/S2/S3
Page 3 of 8
generated with the most significant connection to the
prognosis.
The performance of the drug identification is assessed
by the Effect Score which is the number of prognosis
gene modules with significance divided by the half num-
ber of the identified prognosis gene modules. According
to the ES, we estimated our performance by counting on
the number of positive drug in the ranked drug list.
Result
Characterization of drug sensitivity genes
To assess the potential application of this approach for
identifying compounds, we generated the sensitivity
module for each anti-cancer drug by applying Pearson
correlation coefficient on the GI50 value of each drug
with the NCI60 profiling. After this process, we gathered
140 compounds sensitivity gene sets. The genes which
have significance connection between the biological
response pattern (GI50) and the baseline gene expression,
though may not be directly linked to the primary drug
targets, they should be close to the pathway where the
mechanism of action taking place. Thus these genes can
indicate the key biological processes of drug efficacy and
represent the sensitivity genes of a compound which can
serve as an effective tool for probing the compounds
mechanism of action.
Identification of prognosis gene modules of breast cancer
In order to identify the tumor progression associated
gene modules, we collected three datasets of breast can-
cer, GSE2034 [15], GSE7390 [16] and GSE11121 [17].
Based on the enrichment score of the gene modules in
each dataset, we used t-test to select the gene modules
that has significant statistical different enrichment score
across the patient samples of outcome. Then we
selected the overlap gene modules that shown signifi-
cantly associated to prognosis in all the data. The 30
gene modules were identified and listed in Table 2. As
shown in Table 2, the prognosis modules are most
likely related to the biologic process of cell cycle, and
microtubule related biologic processes and cellular com-
ponents, which was generally reported that has close
association with cancer progression [21].
Investigation on Disease-Drug connection
In order to investigate whether a drug has strong effect
on the gene function module, we used hyper geometric
test on drug sensitivity module with the identified breast
cancer prognostic associated gene module. The corre-
sponding P-value of the hyper geometric test of each
gene module was cut off by 0.05 as significance threshold.
By ranking the number of the associated gene module,
the FDA approved drugs such as Paclitaxel and Etopo-
side, Haloperidol, Mitoxantrone shows connections with
more than half of the gene modules. Paclitaxel is a mito-
tic inhibitor used in cancer chemotherapy [22]. And it is
a FDA approved drug that used to treat patients with
breast and several other kinds of cancers. The Paclitaxel
associated gene modules also shows related significantly
with mitotic cell cycle in the biological process [23]. As
shown in Figure 2 the result also shows that the microtu-
bule of Cellular Component is sensitive to the drug
action of Paclitaxel which has been validated from litera-
ture [24]. Mitoxantrone is also a FDA approved breast
cancer treatment. It is a type II topoisomerase inhibitor
which is an important protein for cell mitosis [25]. As
listed in Table 3, it has 15 associated gene modules.
Furthermore the cell mitosis related biological processes
show significant sensitivity to Mitoxantrone as shown in
Figure 3.
Etoposide is also a topoisomerase inhibitor but haven’t
been reported to treat breast cancer [26]. Our result sug-
gests that etoposide may have potential to experiment
Table 2. Identified Breast cancer Prognostic Gene
Ontology Modules
Prognostic Gene Ontology Modules
1 BP:mitotic spindle elongation
2 BP:M phase of mitotic cell cycle
3 BP:mitotic cell cycle
4 BP:M phase
5 BP:cytokinesis, actomyosin contractile ring assembly
6 BP:negative regulation of type 2 immune response





12 BP:mitotic cell cycle
13 BP:M phase
14 BP:cytokinesis, actomyosin contractile ring assembly
15 BP:regulation of asymmetric cell division
16 BP:cell cycle process
17 BP:chromosome condensation
18 BP:protection from non-homologous end joining at telomere
19 BP:cell cycle cytokinesis
20 BP:meiotic chromosome segregation
21 BP:negative regulation of sister chromatid cohesion
22 BP:cell division
23 BP:maintenance of centrosome location
24 BP:regulation of chromosome segregation
25 BP:mitotic cell cycle G2/M transition decatenation checkpoint
26 CC:condensed nuclear chromosome
27 CC:spindle microtubule
28 CC:DNA topoisomerase complex (ATP-hydrolyzing)
29 CC:chromosome passenger complex
30 CC:macropinocytic cup
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more on breast cancer treatment. Haloperidol, on the
other hand, is not reported as a breast cancer treatment
drug, but has pharmacological effect on increase patients’
risk of breast cancer among women. As a anti-psychotics
drug, it has been reported that generally links to espe-
cially women breast tumor growth [27]. This result
shows that our method could recognize the compound’s
hidden side effect that could not be observed during the
development stage.
Several not FDA approved drugs was also found has
strong association with breast cancer. For example, Ellipti-
cine was ranked also has 18 modules, and it was also
reported that can act as an inhibitor to breast cancer.
However, it fails for its side effect during the development
Figure 2 The distribution of the Drug-Disease network. The yellow node repersents the prognostic gene module of breast cancer. The red
node is denoted for the drug sensitivity module. If the sensitivity module has a significant overlap between the prognostic gene modules, it
means this module is sensitive to this drug which is denoted as a link from the red note to the yellow node. The right circle is the Paclitaxel
related gene modules network.
Table 3. Ranked list of predicted drug that related to breast cancer
Drug name FDA approved Number of associated disease gene module
1 Paclitaxel 1 18
2 Ellipticine 0 18
3 camptothecin 0 17
4 Digitoxigenin 0 17
5 tetrahydroalstonine 0 17
6 Etoposide 1 16
7 Haloperidol 1 16
8 cicloheximide 0 15
9 Genistein 0 15
10 mitoxantrone 1 15
11 podophyllotoxin 0 15
12 Securinine 0 15
Zhu and Zhu BMC Medical Genomics 2015, 8(Suppl 2):S3
http://www.biomedcentral.com/1755-8794/8/S2/S3
Page 5 of 8
[28]. Also, camptothecin, genistein also found to have
strong pharmacological efficiency on breast cancer but
failed by its side effect.
Comparison of gene signatures performance
For comparison, we used gene signature instead of gene
module in our method. The prognostic gene signature was
extracted from GSE2034. We chose 76 genes that are
reported in Wang’s work [15] as the most significantly
related to the prognosis risk. The gene signature was identi-
fied by the same procedure as gene module identification.
Then a ranked list of drugs was produced by the number of
genes overlapped with drug sensitivity modules (Table 4).
Since the corresponding P values are above the threshold of
0.05. The result indicates that the gene signature has the
ability to predict prognosis, however it is not very stable in
the identification of useful drugs for breast cancer.
Discussion and conclusion
In this study, we introduced a new pipeline to interrogate
the transient cellular state under drug conditions by
prognosis gene modules. Different from other methods
which directly map the expression profiles of drug treat-
ment to disease, our method was used to identify the cel-
lular responses of drugs and gene modules that correlated
with tumor progression through patients’ survival infor-
mation. We have identified 30 significant biological pro-
cesses related to breast cancer prognosis gene modules. By
integrating two results of gene modules, we provided valu-
able prediction information of breast cancer potential
treatment. Among the drug library, we identified 12 drugs
for breast cancer treatment. 4 of them are FDA approved
treatment drugs, which shows the efficient of our result.
We provide a novel work to investigate on the drug
sensitivity module by using the prognostic related gene
module annotation and use the connection to discover
new association between the drug and disease. Our
work proved that the sensitivity module of drugs could
be used to not only identify the drug to treat the dis-
ease, but also reveal the drug’s potential side effect.
This method provides a new pipeline to identify the
repositioned compound for diseases. However, there are
Figure 3 The Mitoxantrone associated with gene modules network.
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several parts that could be improved in our future
research. (1) By adopt with different cancer information,
we could investigate more prognostic related gene mod-
ules. (2) The gene module could be extended according
to the definitions of Protein-Protein-Interaction-
Network level, or pathway information, or miRNA regu-
lation. (3) From the disease annotated drug sensitivity
module, such as the Mitoxantrone in Figure 3, it is pos-
sible to further investigation on the drug similarity. We
will further improve our method and make performance
comparison with other works.
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